CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

Engineers have developed a novel method for manufacturing CAR T cells, one that takes just 24 hours and requires only one step, thanks to the use of lipid nanoparticles (LNPs), the potent delivery ...

The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...

Please provide your email address to receive an email when new articles are posted on . After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

LONDON, UK / ACCESSWIRE / January 8, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), which is developing new therapies and treatments for blood diseases, is pleased to announce the successful ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...